BLTE vs POM: fair value comparison
Belite Bio, Inc and Pomdoctor Limited · Updated 2026-10-19
BLTE's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. POM reports in CNY, so no same-currency fair-value verdict is published for it. Within Healthcare, POM currently ranks higher by quality score.
| BLTE | POM | |
|---|---|---|
| Verdict | Awaiting full valuation | Awaiting full valuation |
| Last price | $142.78 | $0.92 |
| 12-month range | $92.22–$193.61 | $0.55–$109.62 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #292 of 301 Healthcare | #290 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | — | Low |
| Margin trend | — | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: BLTE fair value analysis · POM fair value analysis